When Direct Oral Anticoagulants Should Not Be Standard Treatment: Jacc State-Of-The-Art Review

When Direct Oral Anticoagulants Should Not Be Standard Treatment: Jacc State-Of-The-Art Review Publisher Pubmed

Bejjani A^{1, 2, 3} ; Khairani CD^{1, 2} ; Assi A⁴ ; Piazza G^{1, 2, 4} ; Sadeghipour P⁶ ; Talasaz AH^{7, 8} ; Fanikos J⁹ ; Connors JM¹⁰ ; Siegal DM¹¹ ; Barnes GD¹² ; Martin KA¹³ ; Angiolillo DJ¹⁴ ; Kleindorfer D¹⁵ ; Monreal M¹⁶ Show All Authors

Bejjani A^{1, 2, 3}
Khairani CD^{1, 2}
Assi A⁴
Piazza G^{1, 2, 4}
Sadeghipour P⁶
Talasaz AH^{7, 8}
Fanikos J⁹
Connors JM¹⁰
Siegal DM¹¹
Barnes GD¹²
Martin KA¹³
Angiolillo DJ¹⁴
Kleindorfer D¹⁵
Monreal M¹⁶
Jimenez D¹⁷
Middeldorp S¹⁸
Elkind MSV^{19, 20}
Ruff CT²
Goldhaber SZ^{1, 2}
Krumholz HM^{21, 22, 23}
Mehran R²⁴
Cushman M^{25, 26}
Eikelboom JW²⁷
Lip GYH^{28, 29}
Weitz JI^{30, 31}
Lopes RD^{32, 33}
Bikdeli B^{1, 2, 18, 34}

Show Affiliations

1. Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
2. Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
3. Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
4. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
5. Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, Iran
6. Clinical Trial Center, Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, Iran
7. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
8. Virginia Commonwealth University, Richmond, VA, United States
9. Department of Pharmacy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
10. Hematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
11. Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada
12. Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States
13. Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
14. Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, United States
15. University of Cincinnati, Cincinnati, OH, United States
16. Catedra de Enfermedad Tromboembolica, Universidad Catolica San Antonio de Murcia, Spain
17. Respiratory Department, Hospital Ramon y Cajal and Medicine Department, Universidad de Alcala (Instituto de Ramon y Cajal de Investigacion Sanitaria), Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain
18. Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands
19. Department of Neurology, Vagelos College of Physicians and Surgeons, New York, NY, United States
20. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, United States
21. Yale New Haven Hospital/Yale Center for Outcomes Research and Evaluation, New Haven, CT, United States
22. Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, United States
23. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States
24. Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
25. Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States
26. Department of Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States
27. Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada
28. Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
29. Danish Center for Clinical Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
30. McMaster University, Hamilton, ON, Canada
31. Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
32. Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, United States
33. Brazilian Clinical Research Institute, Sao Paulo, Brazil
34. Cardiovascular Research Foundation, New York, NY, United States

Source: Journal of the American College of Cardiology Published:2024

Abstract

For most patients, direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists for stroke prevention in atrial fibrillation and for venous thromboembolism treatment. However, randomized controlled trials suggest that DOACs may not be as efficacious or as safe as the current standard of care in conditions such as mechanical heart valves, thrombotic antiphospholipid syndrome, and atrial fibrillation associated with rheumatic heart disease. DOACs do not provide a net benefit in conditions such as embolic stroke of undetermined source. Their efficacy is uncertain for conditions such as left ventricular thrombus, catheter-associated deep vein thrombosis, cerebral venous sinus thrombosis, and for patients with atrial fibrillation or venous thrombosis who have end-stage renal disease. This paper provides an evidence-based review of randomized controlled trials on DOACs, detailing when they have demonstrated efficacy and safety, when DOACs should not be the standard of care, where their safety and efficacy are uncertain, and areas requiring further research. © 2024 American College of Cardiology Foundation

Related Docs

View other Related Docs

1. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review, JAMA Cardiology (2022)

2. Direct Oral Anticoagulants for Treatment of Venous Thrombosis: Illustrated Review of Appropriate Use, Research and Practice in Thrombosis and Haemostasis (2024)

3. Optimizing Antithrombotic Therapy in Patients With Coexisting Cardiovascular and Gastrointestinal Disease, Nature Reviews Cardiology (2024)

4. Venous Thromboembolism, Practical Cardiology: Principles and Approaches (2022)

5. Dose Discordance of Direct Acting Oral Anticoagulants Using Different Equations for Estimating Gfr: A Literature Review, Expert Review of Clinical Pharmacology (2020)

6. Post-Transcatheter Aortic Valve Replacement Antithrombotic Treatment in Nonindicated Patients: Updated Systematic Review and Network Meta-Analysis, JACC: Advances (2025)

7. Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis, Stroke (2020)

8. Efficacy and Safety of a Doac Compared to Unfractionated Heparin and a Low Molecular Weight Heparin in the Prevention of Thromboembolism in Hematopoietic Stem Cell Transplant Recipients, Iranian Journal of Pharmaceutical Research (2024)

Experts (# of related papers)

View all Related Experts

Azita Hajhossein Talasaz (5)

Kaveh Hosseini (3)

Style	Citing Format
MLA	Bejjani A, et al.. "When Direct Oral Anticoagulants Should Not Be Standard Treatment: Jacc State-Of-The-Art Review." Journal of the American College of Cardiology, vol. 83, no. 3, 2024, pp. 444-465.
APA	Bejjani A, Khairani CD, Assi A, Piazza G, Sadeghipour P, Talasaz AH, Fanikos J, Connors JM, Siegal DM, Barnes GD, Martin KA, Angiolillo DJ, Kleindorfer D, Monreal M, Jimenez D, Middeldorp S, Elkind MSV, Ruff CT, Goldhaber SZ, ... Bikdeli B (2024). When Direct Oral Anticoagulants Should Not Be Standard Treatment: Jacc State-Of-The-Art Review. Journal of the American College of Cardiology, 83(3), 444-465.
Chicago	Bejjani A, Khairani CD, Assi A, Piazza G, Sadeghipour P, Talasaz AH, Fanikos J, et al.. "When Direct Oral Anticoagulants Should Not Be Standard Treatment: Jacc State-Of-The-Art Review." Journal of the American College of Cardiology 83, no. 3 (2024): 444-465.
Harvard	Bejjani A et al. (2024) 'When Direct Oral Anticoagulants Should Not Be Standard Treatment: Jacc State-Of-The-Art Review', Journal of the American College of Cardiology, 83(3), pp. 444-465.
Vancouver	Bejjani A, Khairani CD, Assi A, Piazza G, Sadeghipour P, Talasaz AH, et al.. When Direct Oral Anticoagulants Should Not Be Standard Treatment: Jacc State-Of-The-Art Review. Journal of the American College of Cardiology. 2024;83(3):444-465.
BibTex	@article{ author = {Bejjani A and Khairani CD and Assi A and Piazza G and Sadeghipour P and Talasaz AH and Fanikos J and Connors JM and Siegal DM and Barnes GD and Martin KA and Angiolillo DJ and Kleindorfer D and Monreal M and Jimenez D and Middeldorp S and Elkind MSV and Ruff CT and Goldhaber SZ and Krumholz HM and Mehran R and Cushman M and Eikelboom JW and Lip GYH and Weitz JI and Lopes RD and Bikdeli B}, title = {When Direct Oral Anticoagulants Should Not Be Standard Treatment: Jacc State-Of-The-Art Review}, journal = {Journal of the American College of Cardiology}, volume = {83}, number = {3}, pages = {444-465}, year = {2024} }
RIS	TY - JOUR AU - Bejjani A AU - Khairani CD AU - Assi A AU - Piazza G AU - Sadeghipour P AU - Talasaz AH AU - Fanikos J AU - Connors JM AU - Siegal DM AU - Barnes GD AU - Martin KA AU - Angiolillo DJ AU - Kleindorfer D AU - Monreal M AU - Jimenez D AU - Middeldorp S AU - Elkind MSV AU - Ruff CT AU - Goldhaber SZ AU - Krumholz HM AU - Mehran R AU - Cushman M AU - Eikelboom JW AU - Lip GYH AU - Weitz JI AU - Lopes RD AU - Bikdeli B TI - When Direct Oral Anticoagulants Should Not Be Standard Treatment: Jacc State-Of-The-Art Review JO - Journal of the American College of Cardiology VL - 83 IS - 3 SP - 444 EP - 465 PY - 2024 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract